Ivonescimab Topped Keytruda on Median Lung Cancer Survival by Eight Months in China but Lacks U.S. Approval

Ivonescimab beat Keytruda on survival in a China-only lung cancer trial, but the drug is not approved in the U.S. Here is what patients should know.

Have A Referral?